Several of the drugs on the list of 10 that will face price negotiations may not actually end up on the list, thanks to upcoming generic and biosimilar competition or tactics that companies may use to speed competition.
Of the 10 drugs on CMS’ list, at least four so far —Johnson & Johnson’s Stelara, Novartis’ Entresto, Amgen’s Enbrel and Novo Nordisk’s insulins — may not see negotiations in 2026 due to incoming generic or biosimilar competition.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.